Literature DB >> 3260183

The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities.

J T Hom1, L D Butler, P E Riedl, A M Bendele.   

Abstract

Alterations in the progression of the inflammatory disease in mice with established collagen-induced arthritis (CIA) by in vivo treatments with either anti-T cell antibodies or an immunosuppressive drug, whose main targets of action are T cells, were studied. It was demonstrated that the in vivo administration of either monoclonal anti-L3T4, anti-Ly-2 or the combination of anti-L3T4 and anti-Ly-2 failed to modify the inflammatory disease after the arthritis had been initiated. Nevertheless, the progression of disease was decreased by treatments with rabbit anti-mouse lymphocyte sera (ALS) in mice with established CIA. While there was a substantial reduction in the proliferative responses to the T cell mitogen concanavalin A (Con A) in these ALS-treated mice, proliferation to a B cell mitogen, lipopolysaccharide, was unaffected. Furthermore, treatments with anti-Thy-1.2 monoclonal antibody (mAb) by itself did not alter the progression of the ongoing inflammatory disease, but combined treatments with both anti-Thy-1.2 and anti-L3T4 mAb prevented the further advancement of the arthritic disease. Although mice receiving either anti-Thy-1.2 alone or both anti-Thy-1.2 and anti-L3T4 exhibited complete absence of Thy-1+ cells within their inguinal lymph nodes, the proliferative responses to Con A by LN cells from mice treated with the combination of anti-Thy-1.2 and anti-L3T4 were drastically reduced compared to the responses of either the anti-Thy-1.2 or anti-L3T4-treated groups. Finally, daily treatments with cyclosporin A, an immunosuppressive drug which preferentially acts on T cells, were also effective in modifying the clinical course of the arthritic disease in mice with established CIA. These results suggest that immunocompetent cells which express the Thy-1 surface marker, most likely Thy-1+ T cells, may play a role in maintaining and perpetuating the inflammatory disease of established CIA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260183     DOI: 10.1002/eji.1830180608

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

2.  Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice.

Authors:  G W Cannon; S McCall; B C Cole; M M Griffiths; L A Radov; J R Ward
Journal:  Agents Actions       Date:  1990-03

3.  Monoclonal antibodies and arthritis.

Authors:  M E Billingham; C Hicks; S Carney
Journal:  Agents Actions       Date:  1990-01

4.  Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice.

Authors:  Y Niki; H Yamada; S Seki; T Kikuchi; H Takaishi; Y Toyama; K Fujikawa; N Tada
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Anti-inflammatory properties of zinc protoporphyrin disodium (Zn-PP-2Na).

Authors:  H Nagai; K Kitagaki; K Kuwabara; A Koda
Journal:  Agents Actions       Date:  1992-11

8.  Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice.

Authors:  G J Thorbecke; R Shah; C H Leu; A P Kuruvilla; A M Hardison; M A Palladino
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.

Authors:  I I Singer; D W Kawka; E K Bayne; S A Donatelli; J R Weidner; H R Williams; J M Ayala; R A Mumford; M W Lark; T T Glant
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

10.  Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.

Authors:  R O Williams; L J Mason; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.